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Abstract  
 
Objective: Elderly people with schizophrenia often suffer from cognitive impairments, 
which affect their social functioning. Today, only few therapy approaches for middle-
aged and older patients are available. The Integrated Psychological Therapy (IPT) 
combines neurocognitive and social cognitive interventions with social skills 
approaches. The aim of this study was to evaluate (1) whether IPT is effective in 
younger patients (age<40 years) and middle-aged patients (age≥40 years), and (2) 
whether control conditions (CC: treatment as usual or unspecific group activities) 
reveal some change in outcome depending on age.  
Method: A total of 15 controlled IPT studies with 632 schizophrenia inpatients were 
included into a standard meta-analytic procedure. Studies were categorized into two 
age-categories. 
Results: Significant medium to high effect sizes (ES) were evident for IPT 
independent of age on the global cognitive score (mean score of all cognitive 
variables), on neurocognition, social cognition, social functioning, psychopathology, 
and on the global therapy effect (mean of all variables). The IPT effects in middle-
aged patients were significantly higher on the global cognitive score, on 
neurocognition and on social cognition compared to younger patients. Opposite 
results could be observed in CC. Only younger patients participating in the CC 
showed small but significant ES on these variables, but almost middle-aged control 
patients did not. However, none of the differences in CC were significant between the 
two age-categories. A moderator analysis obtained no evidence for a strong impact 
of IPT variations, therapy setting, patient characteristics and methodological rigor of 
the research design. 
Conclusions: These results support evidence for the efficacy of IPT independent of 
age. Results further indicate the need of goal-oriented specific psychological 
interventions for middle-aged and older schizophrenia patients.  
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There is evidence for a gradual aging of the population in developed countries all 
over the world, and also an increase of middle-aged and elderly schizophrenia 
patients.1 Therefore, research focusing on the impact of the age on schizophrenia 
features as well as on the successful treatment of these features becomes important. 
During the last decades, a large bulk of data was published addressing younger 
people suffering from schizophrenia, but the needs of older schizophrenia patients 
were often neglected. 
Recent reviews of published data on the rehabilitation goals for older people with 
serious mental illness summarized that poor outcome in social functioning and lower 
quality of life are strongly associated with social isolation, depression, cognitive 
impairment, and chronic medical illness.1,2 The authors concluded that specific 
interventions are needed with regard to these specific features associated with social 
functioning and quality of life in older patients. Interventions should enhance social 
integration and involvement in meaningfulness activities and should diminish 
depressive symptoms. Another review of empirical data suggests that positive 
symptoms in schizophrenia patients decrease with age, while negative and 
depressive symptoms are similar in younger and older adults. Additionally, cognitive 
impairments tend to increase with age.3 Therefore, successful interventions on 
cognitive functions may be a promising treatment target to support the rehabilitation 
of the primary intervention topics in older schizophrenia patients. In younger, non-
geriatric people with schizophrenia, a key issue in understanding and treating the 
disease is cognitive functioning. Cognition represent the most powerful empirical 
based predictor of functional recovery.2,4,5 75-85% of schizophrenia patients 
experience long lasting cognitive deficits.6-7 However, inconsistent data are available 
whether the research results based on patients in early stages of the illness can be 
generalized on more geriatric populations.5, 8-11 
Today, only few evaluated therapy approaches are available for middle-aged and 
older schizophrenia patients focusing on the defined treatment targets. A recent 
review1 identified three social skills therapy approaches (SST) for elderly people with 
schizophrenia: the Functional Adaptation Skills Training12 (FAST), Helping Older 
People Experience Success13 (HOPES), and the Cognitive Behavioral Social Skills 
Training14 (CBSST), which combines SST with cognitive-behavioral therapy. 
Furthermore, the review includes a work rehabilitation program.15 All of these 
approaches improved functioning successfully. Furthermore, two cognitive 
remediation therapy approaches (CRT) have already been evaluated in samples of 
middle-aged and older patients: McGurk and Mueser16 used a computer program 
(Cogpack, Marker software) in combination with work rehabilitation, and Wykes and 
colleagues10 administered the classic cognitive remediation therapy.17 However, in 
both studies middle-aged and older patients showed only minimal improvements in 
cognitive functioning compared to significant improvements in younger schizophrenia 
patients. 
Against this background combined therapeutic interventions targeting deficits in 
cognition and social functioning integrated in a multidimensional treatment concept – 
so-called integrated therapy approaches - have received a great deal of interest in 
recent years. The term integrated points out to the necessity that cognitive 
remediation therapy should always be embedded in a broad-based treatment 
concept tailored to the patients` rehabilitative and cognitive resources and deficits. 
One of the first and broadest evaluated approaches is the Integrated Psychological 
Therapy (IPT), which combines neurocognitive and social cognitive remediation with 
therapy of social skills and interpersonal problem solving. 
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Integrated Psychological Therapy (IPT) 
 
IPT is a manualized cognitive behavioral therapy program for groups of 5-8 
schizophrenia patients. Its conceptualization is based on the underlying assumption 
that basic deficits in cognitive functioning have a pervasive effect on higher levels of 
behavioral organization such as social skills and social and independent 
functioning.4,18. Therefore, IPT is structured into five subprograms (SP) with 
increasing levels of complexity that are taught sequentially as a building-block model. 
It begins with neurocognition (SP1: “Cognitive Differentiation”) and social cognition 
(SP2: “Social Perception”), followed by communication (SP3: “Verbal 
Communication”) and social skills (SP4: “Social Skills”) and ends with problem 
solving skills (SP5: Interpersonal Problem Solving”). A detailed description of the IPT 
concept was published in a manual and translated into 13 languages.4 The first study 
on IPT was carried out in 1980 and the initial German manual was published in 
1988.19-20 Today, the sixth German edition of the IPT manual is available.21  
 
METHODS 
 
Over the past 30 years, a large body of research has investigated IPT. Up to now, 
research groups in 12 countries in North and South America, Europe, and Asia have 
conducted 36 studies investigating IPT or a combination of IPT subprograms, with a 
total sample of 1,601 patients with schizophrenia (diagnosed according to ICD or 
DSM). These studies were reviewed and evaluated by meta-analytic research.22-25 
Study identification and selection was based (a) on individual contacts in supervising 
IPT procedure by members of our research group, and (b) on extensive standard 
literature search in international data sources (PsychINFO, Medline, PubMed) using 
the key words “schizophrenia” or “psychosis” and “IPT” or “Integrated Psychological 
Therapy” and “therapy” or “training”. The studies were heterogeneous with regard to 
study characteristics: They used different IPT variations and research designs, were 
applied in inpatient and outpatient settings, in academic and non-academic sites and 
included patients at different stages of illness and age.  
 
Research aims 
 
The primary aim of this study was to evaluate the impact of patient’s age on outcome 
of IPT intervention. We were particularly interested in the cognitive part of IPT 
procedure for the following reasons: (a) the initial part of IPT procedure represents a 
cognitive remediation approach rarely used in the rehabilitation of older 
schizophrenia patients; (b) due to the rate-limiting factor of cognitive deficits, the 
initial cognitive remediation is thought as a requirement for positive treatment effects 
on social functioning. It is therefore defined as the basic mechanism of change in 
integrated interventions. Regarding the age, studies including older populations 
relative to the total sample of all IPT studies were conducted exclusively in inpatient 
settings and did not use active goal-oriented therapy as a control condition. 
Therefore, in order to compare primary studies with younger patients with those 
including older patients we intended to select a homogeneous sample with regard to 
treatment content, setting and design of the large number of different IPT studies.  
 
Study selection 
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For that purpose, we selected all studies of the available 36 IPT studies, in which (a) 
the cognitive subprograms or the complete IPT (including the cognitive and social 
subprograms) were evaluated, (b) the study was conducted in inpatient setting, and 
(c) IPT was controlled by treatment as usual (TAU) or placebo-attention conditions 
(unspecific group activities). Studies focusing exclusively on IPT subprograms 
addressing social competence (K=3 studies), studies in outpatient or mixed setting 
(K=12), studies using other goal-oriented therapy approaches as control condition 
(K=6), studies using no control condition (K=5), or studies including adolescent 
patients (age<18 years; K=1) were excluded. Finally, 15 independent studies on IPT 
(N=632 inpatients) 26-42 could be included into the meta-analytic procedure. Data 
related to the age of the participants were based on two resources: on study 
inclusion and exclusion criteria, and on the mean score (M) and the standard 
deviation (SD) of the inpatient sample. Against this background, we categorized the 
mean age of study participants using the median split method. The mean age of 
patients across the 15 studies was 37.1 years (SD=6.7). The median split method 
revealed two age-categories characterized by younger adult patients of age <40 
years (Range: 28-36 years; K=9 studies; N=493 patients) and near middle-aged 
patients of age ≥40 years (Range: 40-50 years; K=6; N=139). However, there was no 
study that included patients with a mean age between 36 and 50 years. This 
suggests two relatively homogeneous and non-overlapping sub-samples. The mean 
study sample comprised 42.1 patients. Studies that comprised patients with a mean 
age <40 years generally consisted of larger samples (N=54.8 participants) than 
studies with patients’ age ≥40 years (N=23.2). All 15 included studies are described 
in Table 1 in chronological order.  
12 studies were conducted in Europe, one in the USA, Japan and Panama. 8 studies 
evaluated the complete IPT, and 7 studies evaluated the IPT subprograms 
addressing cognition. The different IPT interventions were equally distributed over 
the two age-categories. 9 out of 15 studies used RCT design, 6 studies used a quasi-
randomized design or did not describe patient allocation.  
 
 
Insert Table 1 about here 
 
 
Data analysis 
 
To determine the separate extent of change in adult inpatients across the 
experimental group (IPT) and the control conditions (TAU; placebo-attention) in both 
age categories (age<40 years and age ≥40 years), weighted effect sizes (ES) within 
the four comparison groups (IPT and controls in age<40; IPT and controls in age ≥40 
years) were calculated.  
Effect sizes (ES) were based on the means (M) of IPT and control group in each 
study at baseline and post-therapy, and on the pooled standard deviation (SD) at 
baseline. ES were calculated using the following equations: ES=(Mpost-therapy – 
Mbaseline) / SDpooled baseline. Effect sizes can generally be categorized as small (.2), 
medium (.5), or large (.8).43 Meta-analytic procedure was conducted using the 
method of Rustenbach44 based on Cohen43 and Hedges and Olkin45. Effect sizes 
were weighted by their inverse variance (dw). The outcome was classified into the 
following categories during therapy: global therapy effect (mean of all assessed 
variables), cognition (composite score: mean of all assessed variables addressing 
cognition), neurocognition (composite score), social cognition (composite score), 
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social functioning, psychopathology (composite score), negative symptoms, and 
positive symptoms. Additionally, the cognitive scores were grouped according to the 
definitions of the Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) initiative supported by NIMH. The members of this 
initiative yielded consensus on six relatively distinct neurocognitive domains (speed 
of processing, attention/vigilance, verbal memory, visual memory, working memory, 
and planning/problem solving) and five social cognitive domains (emotion 
processing, social perception, Theory of Mind (ToM)) relevant in schizophrenia.46-47  
If studies included more than one variable of one category, the mean effect size was 
used. When different outcomes of the same study had been published in more than 
one article, the results were combined. Effect size categories and study 
characteristics were rated independently by the authors as well as by a researcher 
with PhD degree, who was not involved in the study.  
We combined the effect sizes using a fixed-effects model. To determine whether the 
mean effect size of an outcome category was statistically significant, the 95%-
confidence interval (CI) of ESw was used. Lower bond of CI>0 indicates a statistically 
significant effect on the 5%-level. The heterogeneity of the effect sizes across studies 
in an outcome domain was evaluated by using the Q statistics.45 The significance 
level of Qw was proved using Chi-Squares values (DF=K-1 studies). When Q 
statistics indicated a heterogeneous mean ESw, an integration of the effect sizes into 
a random-effects size model was conducted.45 Additionally, Q statistics were used to 
compare dw between groups (Qb; DF=K-1 groups) .44 All statistical tests were 
conducted two-tailed. 
To control whether the treatment benefit was affected by moderating factors we 
hypothesized the following moderators when analyzing the total sample of the 15 
included studies: (1) IPT variation (complete IPT vs. cognitive IPT subprograms 
only); (2) strength of research design (randomized vs. not randomized patient 
allocation); (3) significant differences in patient characteristics between the two age-
categories (e.g., IQ, gender, and age to assure the adequacy of the research 
design); and (5) significant differences in the therapy setting between the two age 
categories (e.g., number of sessions, weeks of therapy). If at least 10 studies were 
available, a meta-regression analysis44,45 was carried out using the effect size of an 
outcome as the independent variable and the hypothesized moderators as potential 
predictors. If a potential moderating factor has been statistically identified by the 
meta-regression analysis, it was categorized and its influence on outcome of the age-
categories was controlled using Q statistics.44,45 
 
RESULTS 
 
The patient characteristics of the 15 studies (N=632) are displayed separately for the 
two age categories (age<40 years; age≥40 years) in Table 2. The patient 
characteristics age, distribution of gender, duration of hospitalization and duration of 
illness were all significantly different in the two age-categories. Only the IQ did not 
differ significantly between the two groups. However, only few studies published data 
addressing IQ, duration of hospitalization and illness (DF<9).  
 
 
Insert Table 2 about here 
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Table 3 shows the setting characteristics used in studies addressing the two age-
categories. None of the setting variables was statistically significant between the two 
age categories, although there is a tendency for longer lasting therapy in the older 
age-category. The drop-out rate in studies including younger patients was 16.7% 
(standard deviation SD=20.8) and in studies including middle-aged patients 13.4% 
(SD=13.6).  
 
 
Insert Table 3 about here 
 
 
General outcome 
 
In a first step, all outcome variables were pooled together to generate a mean within-
effect size, which corresponds to the global therapy effect of IPT and control group in 
both age-category settings. Using a fixed-effects model, the medium global therapy 
effect of IPT was significant during therapy in the younger age category (weighted 
effect sizes within the group ESW=.52; 95% confidence interval CI: .39-.65; DF=8 
homogeneity Qw=8.11) as well as in the older age category (ESW=.57; CI=.30-.84; 
DF=5;  Qw=8.84). The difference between these two homogeneous IPT effects was 
not significant (Qb=.13; DF=1; p=.72). However, the IPT effects were larger than 
those of the control conditions in both age groups (Qb>5.75; DF=1; p<.02). 
With regard to the control conditions, only studies with younger patients revealed a 
small but significant effect size (ESw=.24; CI=.10-.38; DF=8; Qw=5.75). Studies with 
almost middle-aged patients showed no effects (ESw=.04; CI=-.04-.30; DF=5; 
Qw=.14). The difference on the global therapy effect between control groups of the 
two age-categories was not significant (Qb=2.32; DF=1; p=.13). 
The effect sizes on cognitive and social functioning and symptoms within IPT and 
control groups are summarized in Table 4. 
 
 
Insert Table 4 about here 
 
 
Outcome in cognition 
 
With regard to the mean scores of cognitive functions, neurocognition and social 
cognition, effects for IPT were twice as large in studies including middle-aged 
patients (high ESw≥.9) than in studies comprising younger patient samples (moderate 
ESw≤.59) (Table 4). These differences were all significant (Qb≥4.71; DF=1; p<.03). 
However, IPT obtained significantly larger effects on these cognitive variables in both 
age-categories compared to controls (Qb≥4.09; DF=1; p<.05). Again, only control 
patients of the younger age category revealed small, significant effect sizes 
(ESw≥.23), while middle-aged patients did not show such effects (ESw≤.19). These 
differences were not significant in any of the described variables (Qb≤.52; DF=1; 
p>.47). 
Dividing the neurocognitive and social cognitive mean scores into cognitive domains 
defined by MATRICS46-47 revealed only enough data for the neurocognitive domains 
of attention/vigilance, memory (pooled data of visual and verbal memory) and 
executive functions (pooled data working memory and planning/problem solving). To 
generate social cognitive MATRICS domains, only enough data were available to 
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pool together a social and emotion perception score. IPT showed significant medium 
to high effects on all cognitive domains in both age categories (ESw≥.43). However, 
the effect size for younger IPT-patients was largely heterogeneous on the cognitive 
domain of attention (Qw=20.91; DF=7; p<.01). This effect size of younger patients 
measuring the change in attention remained significant using a random effect size 
model (ESw=.57; CI=.28-.86). With the exception of the memory score the control 
groups of younger patients revealed smaller but significant effects on these domains 
(ESw≥.23). A comparison of the effects of IPT and the control group in younger 
patients obtained no significant differences between groups (Qb≤3.34; DF=1; p>.06). 
Pattern of results were different in the near middle-aged patient sample: the older 
control patients showed no significant changes in any of the cognitive domains 
defined by MATRICS (ESw≤.2). Furthermore, IPT effects in the middle-aged category 
compared to controls were significantly larger on memory, executive functioning and 
social/emotion perception (Qb≤5.63; DF=1; p<.02), but not on attention (Qb=2.36; 
DF=1; p=.12). Investigating age-related effects in IPT showed significant stronger 
effects in older IPT-patients compared to younger IPT-patients on executive 
functioning (Qb=7.30; DF=1; p<.01) and on social/emotion perception (Qb=17.85; 
DF=1; p<.01), but not in memory and attention (Qb≤.65; DF=1; p>.42). Regarding the 
control groups, no statistically significant difference was evident in any of these 
cognitive domains between the two age-categories (Qb≤2.88; DF=1; p>.08). 
 
Outcome in social functioning  
 
IPT showed significant small to medium effects sizes on social functioning in both 
age-categories (ESw≥.39). It should be considered that the IPT effects in both age-
categories were significantly heterogeneous (younger age category: Qw=9.58; DF=4; 
p=.05; older age category: Qw=11.02; DF=3; p=.01). The IPT effects were stable on a 
level of significance using a random-effect model in younger patients (ESw=.38; CI: 
.17-.59) as well as in middle-aged patients (ESw=.66; CI: .09-1.23). The effects of IPT 
on social functioning did not differ significantly between the two age-categories 
(Qb=.43; DF=1; p=.51). Again, only younger patients in the control group revealed a 
small but significant effect (ESw=.2). This effect was statistically not significantly 
larger than the one of older control patients (Qb=1.24; DF=1; p=.27). Finally, the 
effects on social functioning between IPT and controls did not differ in any of the two 
age-categories (Qb≤1.34; DF=1; p>.24).  
 
Outcome in symptoms  
 
IPT showed significant effects in both age-categories on the mean score of 
psychopathology as well as in reducing positive and negative symptoms (ESw≥.3). 
One exception was an insignificant within-effect on negative symptoms of younger 
IPT-patients (ESw=.15). However, the IPT-effects did not differ significantly between 
the two age-categories on any of these variables (Qb≤2.72; DF=1; p>.09). Again, only 
younger control patients revealed significant effects on psychopathology (ESw=.34) 
and positive symptoms (ESw=.36), whereas middle-aged patients showed zero-effect 
sizes. Moreover, the superiority of younger controls compared to older patients was 
significant on psychopathology (Qb=4.80; DF=1; p=.03) and positive symptoms 
(Qb=4.37; DF=1; p=.04). Only very few studies assessed the change in negative 
symptoms. This should be taken into account when interpreting the following results: 
IPT revealed only in middle-aged patients statistically significant effects (ESw≥.3), 
whereas IPT in younger patient samples and all control conditions did not. Finally, 
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the IPT-effects did not differ significantly from those of controls on any of the 
symptom variables in both age-categories (Qb≤3.80; DF=1; p>.05). However, there 
was a trend on the psychopathology score of younger patients (Qb=3.80; DF=1; 
p=.051) .  
 
Moderator analysis 
 
IPT groups and control groups were dealt with separately when calculating a meta-
regression analysis. We included only effect sizes of outcome as dependent 
variables and moderator variables in the statistical procedure if data of at least ten 
studies were available. The following variables were used as moderator variables: 
IPT variation, strength of research design, age, and gender. Although only few 
studies provided sufficient information about the IQ-score (K=8 studies), it was also 
included because of its hypothesized impact. Furthermore, we included all setting 
variables (duration of therapy, number of sessions) in the analysis although there 
was no statistical difference among age-categories. In the control groups, none of the 
described outcome variables was affected by any of the hypothesized moderator 
variables. In the IPT group, the strongest impact on any outcome variable was found 
for cognitive outcome (composite score). It was moderated by patients’ age 
(regression coefficient B=.03; Z=2.17; p=.03). Additionally, IPT variation (integrated 
vs. non-integrated) was identified to moderate cognitive outcome at an almost 
significant level (B=.25; Z=1.93; p=.06). The strength of research design, gender, IQ, 
and all setting variables addressing length and intensity of therapy did not have an 
impact on effect sizes of any outcome variable summarized in Table 3. 
Consequently, the only identified potential moderator variable besides patients’ age 
at study entry was the factor IPT variation. 
The analysis of IPT variations refers to (a) the effects of integrated cognitive 
remediation therapy combining interventions on neurocognition, social cognition and 
social competence (complete IPT), and (b) the effects of unidirectional 
neurocognitive and/or social cognitive remediation therapy including only IPT 
subprograms addressing cognition (cognitive subprograms). The use of cognitive IPT 
subprograms showed only significant medium to large effects on cognition for 
younger patients (K=4; ESw=.66; CI: .42-.90) as well as for middle-aged patients 
(K=3; ESw=1.02; CI: .62-1.42) using a fixed-effect model. The complete IPT obtained 
a smaller significant medium effect on cognition in younger patients (K=5; ESw=.48; 
CI: .32-.64) compared to a significant large effect in middle-aged patients (K=2; 
ESw=.84; CI: .11-1.57). None of the presented categories regarding age and IPT 
variation differed significantly from each other (Qb≤2.62; DF=1; p>.11). This does not 
support evidence of an impact of IPT variations on outcome.  
 
DISCUSSION 
 
This quantitative review supports evidence that IPT is effective on various outcome 
domains during therapy of younger and near middle-aged inpatients compared to 
TAU or placebo-attention conditions. Significant effects could be observed on 
neurocognition and social cognition. To our knowledge, this is one of the very first 
therapy studies evaluating the outcome of near middle-aged patients in social 
cognition. In general, middle-aged patients showed higher therapy effects on the 
cognitive domains. This effect is in opposite to the results of studies evaluating other 
cognitive remediation approaches for middle-aged and older patients.10,16 Both of 
these approaches did not support group dynamics as it is explicitly used in IPT 
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technology. In contrast to drill and practice exercises within the use of computer 
programs,16 IPT puts emphasis on strategy learning tasks, which may have the 
stronger impact on cognitive functioning.36 Both authors of the two other studies 
concluded that cognitive remediation therapy methods have to be adapted to elderly 
people due to small effects. It should be mentioned that the effects of the two other 
studies might not be comparable to the results of our analysis due to patients’ age. 
The IPT studies including older patients used in this analysis were characterized by 
an age category between 40 to 50 years. This does not represent a geriatric 
population. It can even be discussed whether the older populations’ mean age of 
44.2 years is in accordance with the definition of middle-aged patients. Accordingly, 
the discrepancy in outcome with the two cited studies10,16 may simply be due to age 
effects. The fact that IPT effects were larger in the older age-category than in the 
younger one contradicts the results of other studies and is also contrary to clinicians’ 
expectation about practicing cognitive remediation: the older and the more chronic a 
patient is, the lower his potential for change. One possible explanation of this 
inconsistency may be the group setting of IPT procedure. Consequently supporting 
group processes and group dynamics within IPT may represent a powerful 
mechanism of change. This may especially be the case in the older population. The 
very broad evaluation of IPT has clearly demonstrated, that a group setting alone is 
not sufficient to generate adequate effects. Controlling for unspecific group effects, 
IPT was superior to unspecific group activities on all outcome variables including 
cognition and social functioning. Unspecific group effects obtained higher effects 
compared to TAU.4,22-23 Learning compensation strategies within IPT procedure 
seems to bypass the diminished benefit of repeated exposure to cognitive tasks in 
elderly people.5  
In this study, younger control patients obtained small but significant effects on 
cognition whereas middle-aged, more chronic patients did not. This result may be 
due to better psychiatric (standard) treatments for younger patients than for elderly 
people.10,16 On the other hand, the results may be influenced by a longer experience 
of failure in the treatment of older patients, which makes it harder to motivate them by 
the use of standard treatment tools. At least, there was some evidence that older 
patients are less treatment motivated in work rehabilitation.48-49 These results 
strongly support the recommendation that goal-oriented psychological interventions 
should be offered to middle-aged and older schizophrenia patients.  
Regarding outcome in social functioning, the IPT effects were lower than on cognitive 
outcome, but still significant and independent of age. These results are in 
accordance with the effects found for social skills therapy approaches (FAST, 
HOPES, CBSST).1 Again, only younger control patients showed some small but 
significant change, middle-aged patients did not. However, the difference of effects in 
IPT and control patients regarding age should not be overestimated since it was not 
significant between groups. 
The effects on general symptom reduction and on the positive symptoms were 
contradictory to the effects on the functional areas: Younger IPT-patients obtained 
stronger effects compared to middle-aged patients. However, IPT reached level of 
significance independent of age, as did control groups of younger patients on a lower 
level. Again, middle-aged control patients showed no effects on symptom reduction. 
One possible explanation for different IPT effects between age-categories may be 
derived from another review summarizing the relationship of aging and severity of 
symptoms in schizophrenia.3 This study found evidence that positive symptoms 
decrease with age, while negative symptoms are similar frequent in younger and 
older patients. Only very few of the included IPT studies assessed negative 
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symptoms, which influences the validity of the results. However, middle-aged 
patients showed again stronger effects than did younger patients.  
The moderator analysis identified no relevant effect addressing IPT variation due to 
the limited sample size. It has to be mentioned, that even studies including only the 
cognitive subprograms of IPT represent some kind of integrated approach since they 
combine in many parts neurocognitive and social cognitive remediation therapy 
interventions. The pooled effects of the IPT variation are in line with findings of 
McGurk and colleagues50 that combined interventions have superior effects on more 
distal outcome than unidirectional cognitive interventions.  
The therapy duration and intensity of therapy was different in the two age-categories: 
Younger patients participated more often a week at a therapy session, while the 
therapy duration of middle-aged patients was longer lasting. In summary, the older 
population received more therapy, but none of the setting differences among age-
categories was statistically significant. And neither the therapy duration nor the 
therapy intensity could be identified as moderator influencing outcome. Additionally, 
IQ, gender (percentage of male in the study sample) and the strength of research 
design had an impact on any of the various domains of outcome. However, due to 
the partially very small cell sizes in this analysis, the results may not be decisive in 
negating the impact of these hypothesized moderator variables. 
 
CONCLUSIONS 
 
IPT represents integrated therapy approaches combining interventions on cognition 
with interventions on other therapy targets. The results of this analysis support 
evidence for the efficacy of RCTs as well as some effectiveness in clinical trials 
independent of patients’ age. Results indicate that middle-aged patients clearly 
benefit from the treatment with IPT. Results further indicate the necessity of goal-
oriented specific psychological interventions for near middle-aged schizophrenia 
patients. In opposite to younger control patients, no change in most of the functional 
domains or symptoms was evident during treatment period for the middle-aged 
control patients. However, it has to be mentioned that this analysis was exclusively 
based on the data of inpatient setting not referring to a geriatric population. Up to 
now, sufficient data of middle-aged or older (out)patients participating in IPT are not 
available. The generalization of the results to the population of geriatric patients 
seems to be questionable due to the further development of impairments and 
symptoms with age in both directions. Another limitation of the analysis is the partially 
small cell sizes due to the lack of data as well as the completely missing follow-up 
data for middle-aged patients. Thus, we do not know whether the positive effects 
during therapy could be maintained at follow-up. However, the analysis of all 36 IPT 
studies showed that the therapy effects still improved during follow-up.22-23 Finally, 
other potentially powerful mediators between cognition and functional outcome are 
not considered in the analysis, mediators such as motivation51 or insight (awareness 
of having a mental illness that requires treatment).52 And, the analyzed moderator 
variables in this study - IQ, gender, the duration of treatment – may be influenced by 
the small sample size. Therefore, further research projects on IPT as well as on 
general cognitive remediation therapy should be extended to more geriatric 
populations specifically targeting moderators and mediators in RCT designs including 
long lasting follow-up assessment.  
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TABLE 1.  15 independent IPT studies (N=632) 
  Source Country Intervention N Setting Mean age at study 
entry (years) 
1)  Brenner et al.26-27  Germany Complete IPT 43 inpatient 331 
2)  Stramke et al.28 Switzerland Subprograms 18 inpatient 402 
3)  Hermanutz and Gestrich29 Germany Complete IPT 64 inpatient 281 
4)  Kraemer et al.30 Germany Subprograms 30 inpatient 462 
5)  Roder et al.31 Switzerland Complete IPT 17 inpatient 442 
6)  Funke et al.32 Germany Subprograms 28 inpatient 502 
7)  Heim et al.33 Germany Subprograms 65 inpatient 351 
8)  Olbrich and Mussgay34 Germany Subprograms 30 inpatient 311 
9)  Roder35 Switzerland Subprograms 18 inpatient 331 
10)  Schüttler et al.36; Blumenthal et al.37 Germany Complete IPT 95 inpatient 291 
11)  Gaag van der.38 The Netherlands Subprograms 42 inpatient 311 
12)  Takai et al.39 Japan Complete IPT 34 inpatient 432 
13)  Theilemann.40 Germany Complete IPT 45 inpatient 351 
14)  Spaulding et al.41 USA Complete IPT 91 inpatient 361 
15)  Alguero42 Panama Complete IPT 12 inpatient 432 
N, number of patients 
1age category<40 years.  
2age category≥40 years.  
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TABLE 2.  Patient characteristics of the two age categories 
 Age<40 years  Age≥40 years statistics1 
 Mean SD  Mean SD DF  t   p 
Age (years) 32.3 2.8  44.2 3.3 13 7.6 >.01 
Gender: % male 55.3 7.8  74.1 16.1 12 2.9 .01 
IQ 97.1 1.6  86.4 10.8 7 1.9 .09 
Duration of hospitalization 
(months) 
23.3 23.0  164.4 40.4 8 6.8 >.01 
Duration of illness (years)   8.1 2.6    20.1 1.3 7 6.0 >.01 
M, mean; SD, standard deviation.  
1t.test, two-tailed; DF, degree of freedom; t, t-value; p, significance level. 
 
  22 
 
 
 
 
 
 
 
 
TABLE 3.  Setting variables of the two age categories 
 Age<40 years  Age≥40 years statistics1 
 Mean SD  Mean SD DF  t   p 
Duration of therapy (hours) 40.8 26.0  50.8 26.0 12 .5 .52 
Duration of therapy (weeks) 10.1 6.3  24.3 21.3 13 1.5 .17 
Weekly number of sessions 4.1 1.1  3.3 1.5 13 1.1 .30 
Duration of a session 
(minutes) 
  51.8 14.3    64.0 25.9 12 1.0 .36 
Total number of sessions 38.3 20.4  58.3 34.0 13 1.4 .17 
M, mean; SD, standard deviation. 
1t.test, two-tailed; DF, degree of freedom; t, t-value; p, significance level. 
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TABLE 4.  Effect sizes (ES) within the IPT group and control group regarding the two age categories 
 Age<40 years   Age≥40 years 
 IPT  Control group   IPT  Control group 
 K ESw (95% CI)    QW  ESw (95% CI)   QW  Qb  K ESw (95% CI)    QW  ESw (95% CI)    QW    Qb 
Cognition (mean) 9 .54* (.41-.67) 10.99  .23* (.09-.37) 4.14 10.14*  5 .98* (.63-1.33) 4.47  .12 (-.20-.44) 0.37 12.84* 
Neurocogniton 9 .56* (.43-.69) 15.35  .23* (.09-.37) 4.71 11.37*  5 .90* (.56-1.24) 5.79  .10 (-.22-.42) 0.35 11.32* 
    Attention 8 .54* (40-.68) 20.91*  .11 (.,04-.26) 8.48 1.891  3 .53* (.16-.90) 0.07  .11 (-.28-.50) 1.45 2.36 
    Memory 7 .52* (.37-.67) 8.85  .36* (.20-.52) 6.91 1.98  4 .65* (.32-.98) 0.39  .07 (-.28-.42) 1.66 5.63* 
    Executive functions 7 .43* (.28-.58) 5.72  .23* (.07-.39) 2.37 3.34  4 1.05* (.66-1.44) 6.44  .-.05 (-.4-.30) 2.71 14.11* 
Social cognition 5 .59* (.42-.76) 3.57  .31* (13-.49) 1.08 4.09*  4 1.43* (1.0-1.86) 0.46  .19 (-.16-.54) 0.51 20.09* 
    Social/emotion perception 4 .52* (.32-.72) 1.59  .24* (.02-.46) 0.09 3.31  3 1.40*(.94-1.86) 0.26  .20 (-.19-.59) 0.60 15.85* 
Social functioning 5 .39* (.22-.56) 9.58*  .20* (.01-.39) 4.58 0.411  4 .48*(.12-.84) 11.02*  .01 (-.31-.33) 0.24 1.341 
Psychopathology (mean) 7 .55* (.41-.69) 12.45  .34* (.18-.50) 1.70 3.80  4 .30* (.01-.59) 0.56  .00 (-.30-.30) 0.17 2.03 
    Positive symptoms 6 .54* (.39-.69) 3.98  .36* (.19-.53) 1.35 2.63  4 .31* (.02-.60) 0.34  .00 (-.30-.30) 0.72 2.16 
    Negative symptoms 2 .15 (-.08-.38) 1.72  .18 (-.07-.43) 0.56 0.03  3 .36* (.03-.69) 2.15  .08 (-.25-.41) 1.16 1.40 
K, number of studies; N, number of patients; ESw, weighted effect sizes within the group; 95% CI, 95% confidence interval; Qw, homogeneity statistics, χ2-
test, df=K-1; Qb, homogeneity statistics between IPT and control group in each age category, χ2-test, df=1, 
1based on values of a random effect size model 
due to heterogeneous QW, *p<.05. 
 
 
